Raushan T Kurmasheva

List of Publications by Year
in descending order

91 papers	2,568 citations	29 h-index (172457)	47 g-index (214800)
94 all docs	94 docs citations	94 times ranked	4522 citing authors

#	Article	IF	Citations
1	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood, 2016, 128, 1382-1395.	1.4	148
2	The Insulin-like Growth Factor-1 Receptorâ€"Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma. Cancer Research, 2009, 69, 7662-7671.	0.9	143
3	IGF-I mediated survival pathways in normal and malignant cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 1-22.	7.4	111
4	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports, 2019, 29, 1675-1689.e9.	6.4	103
5	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clinical Cancer Research, 2015, 21, 819-832.	7.0	100
6	Initial testing (stage 1) of tazemetostat (EPZâ€6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2017, 64, e26218.	1.5	86
7	Predicted mechanisms of resistance to mTOR inhibitors. British Journal of Cancer, 2006, 95, 955-960.	6.4	82
8	Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 1325-1332.	1.5	77
9	IRS-1: Auditing the effectiveness of mTOR inhibitors. Cancer Cell, 2006, 9, 153-155.	16.8	70
10	Cell and Molecular Determinants of <i>In Vivo</i> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts. Clinical Cancer Research, 2014, 20, 4520-4531.	7.0	67
11	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: <i>PALB2</i> mutation predicts exceptional <i>in vivo</i> response to BMN 673. Pediatric Blood and Cancer, 2015, 62, 91-98.	1.5	65
12	Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2. Molecular Cancer Therapeutics, 2012, 11, 649-659.	4.1	60
13	Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. Clinical Cancer Research, 2019, 25, 2278-2289.	7.0	57
14	Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 633-641.	1.5	55
15	The B7-H3â€"Targeting Antibodyâ€"Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clinical Cancer Research, 2021, 27, 2938-2946.	7.0	55
16	Evaluation of Alternative <i>In Vivo</i> Drug Screening Methodology: A Single Mouse Analysis. Cancer Research, 2016, 76, 5798-5809.	0.9	52
17	Î"Np63 Promotes Pediatric Neuroblastoma and Osteosarcoma by Regulating Tumor Angiogenesis. Cancer Research, 2014, 74, 320-329.	0.9	51
18	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an <i>In Vivo</i> Model of Childhood Astrocytoma. Clinical Cancer Research, 2013, 19, 6716-6729.	7.0	50

#	Article	IF	Citations
19	AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood, 2015, 126, 1193-1202.	1.4	50
20	Evaluation of the <i>In Vitro</i> and <i>In Vivo</i> Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2015, 14, 364-374.	4.1	49
21	Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Molecular Cancer Therapeutics, 2007, 6, 1620-1628.	4.1	47
22	Initial testing (stage 1) of the poloâ€like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2014, 61, 158-164.	1.5	46
23	Effective Targeting of the P53â€“MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2015, 21, 1395-1405.	7.0	43
24	Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2014, 61, 245-252.	1.5	37
25	Testing of the Akt/PKB inhibitor MKâ€2206 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 518-524.	1.5	36
26	Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1816-1821.	1.5	35
27	Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 586-588.	1.5	33
28	Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a Î³â€secretase inhibitor targeting notch signaling. Pediatric Blood and Cancer, 2012, 58, 815-818.	1.5	31
29	Initial testing (stage 1) of the tubulin binding agent nanoparticle albuminâ€bound (<i>nab</i>) paclitaxel (Abraxane^{Â®}) by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 2015, 62, 1214-1221.	1.5	29
30	Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPTâ€330): A report from the pediatric preclinical testing program. Pediatric Blood and Cancer, 2016, 63, 276-286.	1.5	28
31	Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 1860-1867.	1.5	27
32	Initial Testing (Stage 1) of MKâ€8242â€"A Novel MDM2 Inhibitorâ€"by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2016, 63, 1744-1752.	1.5	27
33	Upstream CpG island methylation of thePAX3 gene in human rhabdomyosarcomas. Pediatric Blood and Cancer, 2005, 44, 328-337.	1.5	26
34	Inhibition of MDM2 by RG7388 confers hypersensitivity to Xâ€radiation in xenograft models of childhood sarcoma. Pediatric Blood and Cancer, 2015, 62, 1345-1352.	1.5	23
35	Initial testing of JNJâ€26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 329-332.	1.5	22
36	Initial testing (stage 1) of M6620 (formerly VXâ€970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2018, 65, e26825.	1.5	21

#	Article	IF	Citations
37	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. Cancer Research, 2016, 76, 4579-4591.	0.9	20
38	Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2017, 64, e26304.	1.5	20
39	Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells. Oncogene, 2008, 27, 694-699.	5.9	19
40	Initial testing (stage 1) of the phosphatidylinositol 3â€² kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 791-798.	1.5	19
41	Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1486-1489.	1.5	19
42	Preclinical activity of the antibodyâ€drug conjugate denintuzumab mafodotin (SGNâ€CD19A) against pediatric acute lymphoblastic leukemia xenografts. Pediatric Blood and Cancer, 2019, 66, e27765.	1.5	19
43	Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma. Frontiers in Oncology, 2019, 9, 1416.	2.8	17
44	Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia. Cancer Research, 2016, 76, 2766-2777.	0.9	16
45	Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. Clinical Cancer Research, 2017, 23, 3744-3755.	7.0	16
46	Evaluation of entinostat alone and in combination with standardâ€ofâ€care cytotoxic agents against rhabdomyosarcoma xenograft models. Pediatric Blood and Cancer, 2019, 66, e27820.	1.5	16
47	Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. Pediatric Blood and Cancer, 2015, 62, 1768-1774.	1.5	15
48	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2017, 64, e26263.	1.5	15
49	Initial testing (stage 1) of the antiâ€microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2015, 62, 1897-1905.	1.5	14
50	Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. Frontiers in Oncology, 2015, 5, 193.	2.8	14
51	In vivo evaluation of the lysineâ€specific demethylase (KDM1A/LSD1) inhibitor SPâ€2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). Pediatric Blood and Cancer, 2021, 68, e29304.	1.5	14
52	Pediatric oncology. Current Opinion in Chemical Biology, 2007, 11, 424-432.	6.1	13
53	Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 783-790.	1.5	13
54	Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews, 2019, 71, 671-697.	16.0	13

#	Article	IF	Citations
55	Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. Pediatric Blood and Cancer, 2020, 67, e28098.	1.5	13
56	FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3â€“FOXO1 Fusion Gene. Clinical Cancer Research, 2014, 20, 3884-3895.	7.0	12
57	Identifying novel therapeutic agents using xenograft models of pediatric cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 221-232.	2.3	12
58	Prospective use of the single-mouse experimental design for the evaluation of PLX038A. Cancer Chemotherapy and Pharmacology, 2020, 85, 251-263.	2.3	12
59	Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. Molecular Cancer Therapeutics, 2022, 21, 903-913.	4.1	12
60	Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts. Clinical Cancer Research, 2020, 26, 3012-3023.	7.0	11
61	Recent Developments in Nanomedicine for Pediatric Cancer. Journal of Clinical Medicine, 2021, 10, 1437.	2.4	11
62	The application of radiation therapy to the pediatric preclinical testing program (PPTP): Results of a pilot study in rhabdomyosarcoma. Pediatric Blood and Cancer, 2013, 60, 377-382.	1.5	10
63	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. Cancer Research, 2021, 81, 1076-1086.	0.9	10
64	Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2015, 62, 1106-1109.	1.5	9
65	Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatric Blood and Cancer, 2018, 65, e26870.	1.5	9
66	Doseâ€response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. Pediatric Blood and Cancer, 2020, 67, e28606.	1.5	9
67	Evaluation of VTPâ€50469, a meninâ€MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium. Pediatric Blood and Cancer, 2020, 67, e28284.	1.5	9
68	In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical modelsâ€"A report from the Pediatric Preclinical Testing Consortium. Pediatric Blood and Cancer, 2021, 68, e28772.	1.5	9
69	PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models. Nucleic Acids Research, 2021, 49, D1321-D1327.	14.5	9
70	Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatric Blood and Cancer, 2012, 59, 753-755.	1.5	8
71	Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatric Blood and Cancer, 2020, 67, e28222.	1.5	8
72	Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1972-1979.	1.5	7

#	Article	IF	Citations
73	Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 922-924.	1.5	6
74	Initial testing (stage 1) of the notch inhibitor PFâ€03084014, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1493-1496.	1.5	6
75	Abstract LB-353: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib.. Cancer Research, 2013, 73, LB-353-LB-353.	0.9	6
76	Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 380-382.	1.5	5
77	Abstract LB-217: Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC). , 2020, , .		4
78	Developing new agents for the treatment of childhood cancer. Current Opinion in Investigational Drugs, 2005, 6, 1215-27.	2.3	4
79	Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing. Journal of Clinical Medicine, 2021, 10, 1504.	2.4	3
80	Birinapant (TL32711), a Small Molecule Smac Mimetic, Induces Regressions in Childhood Acute Lymphoblastic Leukemia (ALL) Xenografts That Express TNFÎ± and Synergizes with TNFÎ± in Vitro â€“ A Report From the Pediatric Preclinical Testing Program (PPTP). Blood, 2012, 120, 3565-3565.	1.4	3
81	PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma. IScience, 2022, 25, 103725.	4.1	3
82	The Use of Pediatric Patient-Derived Xenografts for Identifying Novel Agents and Combinations. Molecular and Translational Medicine, 2017, , 133-159.	0.4	2
83	Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia. Blood, 2012, 120, 3562-3562.	1.4	2
84	Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 80-89.	2.1	2
85	Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric <i>BRAFV600E</i> Brain Tumor Models. Clinical Cancer Research, 2022, 28, 3836-3849.	7.0	2
86	Effective Targeting Of The P53/MDM2 Axis In Preclinical Models Of Infant MLL-Rearranged Acute Lymphoblastic Leukemia. Blood, 2013, 122, 71-71.	1.4	1
87	Molecular Therapy for Rhabdomyosarcoma. , 2010, , 425-458.		0
88	Preclinical models of childhood cancer for the development of targeted therapies. Drug Discovery Today: Disease Models, 2016, 21, 3-9.	1.2	0
89	Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2016, 63, 443-450.	1.5	0
90	The application of radiotherapy to the pediatric preclinical testing program: Results of a pilot study.. Journal of Clinical Oncology, 2012, 30, 9544-9544.	1.6	0

#	Article	IF	Citations
91	Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling. Blood, 2014, 124, 969-969.	1.4	0